The main purpose of the NOPSAD collection is to aggregate standardised jurisdictional data on the number of clients accessing pharmacotherapy for the treatment of opioid dependence, the number of prescribers participating in the delivery of pharmacotherapy treatment, and quantitative information about the prescribing sector. As such, national information on pharmacotherapy can be reported.
Collection details
|
Temporal coverage
from 30/6/2004 to 30/6/2020
|
|
Geographical coverage
National and State
|
|
Data availability
- Publications
- Summary tables published in electronic form
- Statistics
Client specified tables on request which may be subject to data provider approval (charges apply).
Unit records are not available.
|
|
Data scope
The collection covers the provision of opioid pharmacotherapy treatment, the practitioners who prescribe the treatment, the dosing sites who dispense the pharmacotherapy drugs, and the clients receiving the opioid pharmacotherapy treatment. The following pharmacotherapies are currently recommended for the treatment of opioid dependency:
- Methadone hydrochlorideMethadone Syrup®
- Biodone Forte ®
- BuprenorphineSubutex®
- Buprenorphine/NaloxoneSuboxone®.
|
|
Methodology
Official
|
|
Metadata information and data quality statement (DQS)
NOPSAD DQS 2021
|
|
External links and information
National Opioid Pharmacotherapy Statistics Annual Data Collection (NOPSAD) 2021
Alcohol and other drug treatment services in Australia 2020–21
|
|
Contact
[email protected]
|
